Effect of alkyl glycerophosphate on the activation of peroxisome proliferator-activated receptor gamma and glucose uptake in C2C12 cells

Biochemical and Biophysical Research Communications

Volumn 433, Issue 3, 2013, Pages 281-285

  Tsukahara, Tamotsu ^a   Haniu, Hisao ^a   Matsuda, Yoshikazu ^b  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NIHON PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Glucose uptake; Lysophospholipid; Nuclear receptor

Indexed keywords

ALKYL GLYCEROPHOSPHATE; GLUCOSE; GLYCEROPHOSPHATE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; GLUCOSE TRANSPORT; LIPID STORAGE; MOUSE; MUSCLE CELL; MYOBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; SKELETAL MUSCLE;

ANIMALS; BIOLOGICAL TRANSPORT; CELL LINE; GENE EXPRESSION REGULATION; GENES, REPORTER; GLUCOSE; GLYCEROPHOSPHATES; MICE; MUSCLE, SKELETAL; MYOBLASTS; PPAR GAMMA; SIGNAL TRANSDUCTION;

EID: 84876325476     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.02.101     Document Type: Article

References (19)

1. Spector A.A. Fatty acid binding to plasma albumin. J. Lipid Res. 1975, 16:165-179.
2. Corcoran M.P., Lamon-Fava S., Fielding R.A. Skeletal muscle lipid deposition and insulin resistance: effect of dietary fatty acids and exercise. Am. J. Clin. Nutr. 2007, 85:662-677.
3. Leonardini A., Laviola L., Perrini S., Natalicchio A., Giorgino F. Cross-talk between PPARgamma and insulin signaling and modulation of insulin sensitivity. PPAR Res. 2009, 2009:818945.
4. Rangwala S.M., Lazar M.A. Peroxisome proliferator-activated receptor gamma in diabetes and metabolism. Trends Pharmacol. Sci. 2004, 25:331-336.
5. Bryant N.J., Govers R., James D.E. Regulated transport of the glucose transporter GLUT4. Nat. Rev. Mol. Cell Biol. 2002, 3:267-277.
6. Kotliar N., Pilch P.F. Expression of the glucose transporter isoform GLUT 4 is insufficient to confer insulin-regulatable hexose uptake to cultured muscle cells. Mol. Endocrinol. 1992, 6:337-345.
7. Tortorella L.L., Pilch P.F. C2C12 myocytes lack an insulin-responsive vesicular compartment despite dexamethasone-induced GLUT4 expression. Am. J. Physiol. Endocrinol. Metab. 2002, 283:E514-524.
8. Tsukahara T., Tsukahara R., Yasuda S., Makarova N., Valentine W.J., Allison P., Yuan H., Baker D.L., Li Z., Bittman R., Parrill A., Tigyi G. Different residues mediate recognition of 1-O-oleyllysophosphatidic acid and rosiglitazone in the ligand binding domain of peroxisome proliferator-activated receptor gamma. J. Biol. Chem. 2006, 281:3398-3407.
9. Tsukahara T., Tsukahara R., Fujiwara Y., Yue J., Cheng Y., Guo H., Bolen A., Zhang C., Balazs L., Re F., Du G., Frohman M.A., Baker D.L., Parrill A.L., Uchiyama A., Kobayashi T., Murakami-Murofushi K., Tigyi G. Phospholipase D2-dependent inhibition of the nuclear hormone receptor PPARgamma by cyclic phosphatidic acid. Mol. Cell 2010, 39:421-432.
10. Gaits F., Fourcade O., Le Balle F., Gueguen G., Gaige B., Gassama-Diagne A., Fauvel J., Salles J.P., Mauco G., Simon M.F., Chap H. Lysophosphatidic acid as a phospholipid mediator: pathways of synthesis. FEBS Lett. 1997, 410:54-58.
11. Sugiura T., Nakane S., Kishimoto S., Waku K., Yoshioka Y., Tokumura A. Lysophosphatidic acid, a growth factor-like lipid, in the saliva. J. Lipid Res. 2002, 43:2049-2055.
12. Sugiura T., Nakane S., Kishimoto S., Waku K., Yoshioka Y., Tokumura A., Hanahan D.J. Occurrence of lysophosphatidic acid and its alkyl ether-linked analog in rat brain and comparison of their biological activities toward cultured neural cells. Biochim. Biophys. Acta 1999, 1440:194-204.
13. Zierath J.R., Ryder J.W., Doebber T., Woods J., Wu M., Ventre J., Li Z., McCrary C., Berger J., Zhang B., Moller D.E. Role of skeletal muscle in thiazolidinedione insulin sensitizer (PPARgamma agonist) action. Endocrinology 1998, 139:5034-5041.
14. Nesto R.W., Bell D., Bonow R.O., Fonseca V., Grundy S.M., Horton E.S., Le Winter M., Porte D., Semenkovich C.F., Smith S., Young L.H., Kahn R. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004, 27:256-263.
15. Tontonoz P., Hu E., Spiegelman B.M. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 1994, 79:1147-1156.
16. Tontonoz P., Hu E., Graves R.A., Budavari A.I., Spiegelman B.M. MPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 1994, 8:1224-1234.
17. Grimaldi P.A., Teboul L., Inadera H., Gaillard D., Amri E.Z. Trans-differentiation of myoblasts to adipoblasts: triggering effects of fatty acids and thiazolidinediones. Prostaglandins Leukot. Essent. Fatty Acids 1997, 57:71-75.
18. Goodpaster B.H., He J., Watkins S., Kelley D.E. Skeletal muscle lipid content and insulin resistance: evidence for a paradox in endurance-trained athletes. J. Clin. Endocrinol. Metab. 2001, 86:5755-5761.
19. Gross D.N., Farmer S.R., Pilch P.F. Glut4 storage vesicles without Glut4: transcriptional regulation of insulin-dependent vesicular traffic. Mol. Cell. Biol. 2004, 24:7151-7162.